Compare TRDA & FUND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRDA | FUND |
|---|---|---|
| Founded | 2016 | 1988 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.5M | 303.4M |
| IPO Year | 2021 | N/A |
| Metric | TRDA | FUND |
|---|---|---|
| Price | $6.97 | $9.63 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $21.00 | N/A |
| AVG Volume (30 Days) | ★ 252.6K | 17.6K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.64% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.93 |
| Revenue | ★ $25,421,000.00 | N/A |
| Revenue This Year | $39.97 | N/A |
| Revenue Next Year | $50.80 | N/A |
| P/E Ratio | ★ N/A | $10.48 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.93 | $7.39 |
| 52 Week High | $16.45 | $10.47 |
| Indicator | TRDA | FUND |
|---|---|---|
| Relative Strength Index (RSI) | 45.70 | 35.22 |
| Support Level | $5.75 | $9.31 |
| Resistance Level | $7.02 | $10.07 |
| Average True Range (ATR) | 0.47 | 0.19 |
| MACD | 0.27 | -0.07 |
| Stochastic Oscillator | 72.36 | 13.40 |
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, the Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.